Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +5.51% | -66.37% | +0.00% | +0.00% | -100.00% |
| Gross Profit Growth | +0.00% | -86.74% | -100.00% | +0.00% | -100.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -121.09% | -232.94% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -102.02% | -177.39% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -114.92% | -202.34% |
| Weighted Average Shares Growth | +4071.68% | +1206.14% | +1123.54% | +41.50% | +72.24% |
| Weighted Average Shares Diluted Growth | +5434.53% | +1206.14% | +1123.54% | +41.50% | +29.83% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -35.11% | +349.26% | -100.00% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +236.37% | +618.01% | +11.96% | +16.87% | +27.06% |
| Book Value per Share Growth | -96.56% | +39.45% | +0.00% | +0.00% | +152.19% |
| Debt Growth | +2.61% | +5.77% | +46.97% | +23.91% | +364.55% |
| R&D Expense Growth | +663.65% | +338.30% | -69.24% | +199.19% | +42.81% |
| SG&A Expenses Growth | +72.13% | +95.55% | +73.69% | +15.77% | +30.12% |